Literature DB >> 11034541

Genetic predisposition and somatic diversification in tumor development and progression.

D Shibata1, L A Aaltonen.   

Abstract

Studies on human cancer predisposition syndromes have contributed significantly to our understanding on tumor initiation and progression. Work performed on hereditary colon cancer has been particularly fruitful. Much of the molecular background of the various intestinal polyposis syndromes, such as familial adenomatous polyposis (FAP), juvenile polyposis, and Peutz-Jeghers syndrome, has been revealed, pinpointing several key cancer-associated genes. Studies on hereditary nonpolyposis colorectal cancer (HNPCC) have revealed a novel mechanism of tumorigenesis; genomic instability caused by defective DNA mismatch repair (MMR). Understanding the molecular background of these diseases helps us to understand tumor initiation in the affected individuals. Relatively little is known about the details of tumor progression in hereditary and sporadic neoplasia. Certain additional gene mutations can be associated with advancing stages of the disease, but the pace and tempo of the process have remained obscure. A high mutation rate in MMR-deficient tumors has provided a new approach in the analysis of human tumor dynamics. Microsatellite (MS) sequences are frequently mutated in MMR deficient tumors. The high mutation rate allows the use of microsatellite mutations as a tool for analyzing the past patterns of tumor progression. This approach is similar to the use of MS mutations in studying human evolution and migrations. Such tumor studies have revealed progression pathways that differ from the classic adenoma-cancer sequence. The reasons why and how molecular clocks may reveal something new about a well-studied problem are discussed.

Entities:  

Mesh:

Year:  2001        PMID: 11034541     DOI: 10.1016/s0065-230x(01)80013-0

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  6 in total

1.  Proximal and progressive: adenomas in HNPCC.

Authors:  D T Bishop
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

2.  Functional significance of concomitant inactivation of hMLH1 and hMSH6 in tumor cells of the microsatellite mutator phenotype.

Authors:  S Baranovskaya; J L Soto; M Perucho; S R Malkhosyan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-11       Impact factor: 11.205

3.  The expression of BTG1 is downregulated in nasopharyngeal carcinoma and possibly associated with tumour metastasis.

Authors:  G G Sun; Y D Wang; Y J Cheng; W N Hu
Journal:  Mol Biol Rep       Date:  2014-07-02       Impact factor: 2.316

4.  BTG1 underexpression is an independent prognostic marker in esophageal squamous cell carcinoma.

Authors:  G G Sun; Y D Wang; Y J Cheng; W N Hu
Journal:  Tumour Biol       Date:  2014-06-27

5.  Human mismatch-repair protein MutL homologue 1 (MLH1) interacts with Escherichia coli MutL and MutS in vivo and in vitro: a simple genetic system to assay MLH1 function.

Authors:  Barbara Quaresima; Pietro Alifano; Pierfrancesco Tassone; Enrico V Avvedimento; Francesco S Costanzo; Salvatore Venuta
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

6.  B-cell translocation gene 1 is downregulated by promoter methylation in ovarian carcinoma.

Authors:  Ji-Ye Kim; Sung-Im Do; Go Eun Bae; Hyun-Soo Kim
Journal:  J Cancer       Date:  2017-08-22       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.